Company Presentation

Gnubiotics Sciences SA, established in 2016, focuses on applying glycobiology to create unique therapeutics for unmet medical needs. Their GENESIS platform integrates four key technologies, leading to the development of GNU101 targeting ICI-resistant epithelial cancers like MSS CRC, TNBC and melanoma. Over ten preclinical trials show significant tumor reduction, particularly in MSS CRC. GNU101’s innovative mechanism of action activates the adaptive immune system, in particular strong cytotoxic T-cell activity within the TME, suggesting broader cancer treatment potential. Gnubiotics GNU101 is IND-ready and aims initiate clinical trials Q2 2025, targeting MSS CRC which is resistant to current therapies like anti-PD-1, representing a significant unmet medical need.